AARTI DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 503.6 INR | -1.82% |
|
-3.57% | +2.93% |
| 06-18 | Aarti Drugs Reports Fire Incident at Tarapur, India Unit | MT |
| 05-06 | Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024 |
| Sales 2024 | 25.29B 303M 23.96B | Sales 2025 * | 27.64B 331M 26.2B | Capitalization | 46.34B 555M 43.91B |
|---|---|---|---|---|---|
| Net income 2024 | 1.71B 20.54M 1.62B | Net income 2025 * | 2.38B 28.46M 2.25B | EV / Sales 2024 | 1.58 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 |
23.4
x | P/E ratio 2025 * |
19.7
x | Employees | 1,003 |
| Yield 2024 * |
0.93% | Yield 2025 * |
1.27% | Free-Float | 38.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aarti Drugs Limited
| 1 day | -1.82% | ||
| 1 week | -3.57% | ||
| Current month | +5.59% | ||
| 1 month | +2.26% | ||
| 3 months | +13.62% | ||
| 6 months | +1.94% | ||
| Current year | +2.93% |
1 week
501.40
530.00
1 month
451.05538.95
Current year
431.05568.00
1 year
431.05645.75
3 years
313.90749.75
5 years
105.251 026.95
10 years
63.131 026.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 04/01/85 | |
Adhish P. Patil
DFI | Director of Finance/CFO | 41 | 05/07/12 |
Rushikesh Deole
CMP | Compliance Officer | - | 22/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 04/01/85 | |
| Director/Board Member | 61 | 01/01/87 | |
| Director/Board Member | 60 | 14/09/95 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/06/24 | 503.6 | -1.82% | 90 019 |
| 26/06/24 | 512.9 | -0.76% | 64,767 |
| 25/06/24 | 516.8 | +0.24% | 119,905 |
| 24/06/24 | 515.6 | +1.17% | 107,098 |
| 21/06/24 | 509.6 | -2.26% | 217,478 |
Delayed Quote NSE India S.E., June 27, 2024 at 12:43 pm
More quotes
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
Sector
Pharmaceuticals
Calendar
24/07/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
504
INR
Average target price
542
INR
Spread / Average Target
+7.54%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +55.05% | 811B | |
| +43.62% | 640B | |
| -7.14% | 353B | |
| +17.85% | 333B | |
| +8.92% | 302B | |
| +16.30% | 246B | |
| +2.41% | 225B | |
| +12.47% | 218B | |
| +8.57% | 168B |
- Stock Market
- Equities
- AARTIDRUGS Stock
- AARTIDRUGS Stock
